Nuclear magnetic resonance (NMR) imaging is an emerging diagnostic tool capable of tomographic imaging of humans without the use of ionizing radiation. Two NMR imagers, developed in our department, utilize the magnetic behavior of hydrogen nuclei and depict their distribution and magnetic relaxation characteristic within bodily tissues.
The aims of this project are to better define by animal experimentation the diagnostic benefits, the toxicity, and the pharamacology of nitroxide stable free radicals (NSFR) used in vivo as NMR contrast agents. The proposed investigations require the combined disciplines of diagnostic imaging, synthetic chemistry, physics and pharmacology. Preliminary studies in animals show that NSFR, a group of organic paramagnetic compounds used as contrast media can enhance the NMR contrast differences between urinary structures and surrounding tissues and permit evaluation of renal function. Tested NSFR are rapidly excreted by glomerular filtration and appear within urinary structures to produce a dramatic increase in the NMR intensity signal. NSFR, like many radiographic contrast media, are largely excluded from the central nervous system by the normally functioning blood-brain barrier. It is postulated that these contrast media will penetrate into the brain in pathologic conditions and thereby aid in the NMR identification of neurologic diseases. To achieve other organ-specific targetting, NSFR may be covalently conjugated to biomolecules including proteins and lipids. Aggregated particles of NSFR-protein and/or NSFR-liposomes may be diagnostically useful in NMR imaging of the liver and spleen by depicting the functional reticulo- endothelial system. These contrast-enhancing applications of NSFR would substantially add to the diagnostic utility of NMR imaging. Preliminary toxicity studies indicate safety of NSFR. Toxic doses far exceed those necessary for contrast enhancement. The long-term goal is to develop clinically useful NMR contrast agents for use in the diagnosis of human diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK)
Type
Research Project (R01)
Project #
5R01AM031937-03
Application #
3152384
Study Section
Diagnostic Radiology Study Section (RNM)
Project Start
1983-02-01
Project End
1986-06-30
Budget Start
1985-02-01
Budget End
1986-06-30
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Okada, Y; Aoki, S; Barkovich, A J et al. (1989) Cranial bone marrow in children: assessment of normal development with MR imaging. Radiology 171:161-4
Sievers, R E; Schmiedl, U; Wolfe, C L et al. (1989) A model of acute regional myocardial ischemia and reperfusion in the rat. Magn Reson Med 10:172-81
Paajanen, H; Brasch, R C; Dean, P B (1988) Experimental acute pancreatitis: MR relaxation time studies using gadolinium-DTPA. Magn Reson Med 6:63-73
Schmiedl, U; Paajanen, H; Arakawa, M et al. (1988) MR imaging of liver abscesses;application of Gd-DTPA. Magn Reson Imaging 6:9-16
Gordon, D G; Brasch, R C; Ogan, M D et al. (1988) Pyrroxamide, a nonionic nitroxyl spin label contrast agent for magnetic resonance imaging. Mutagenesis and cell survival. Invest Radiol 23:616-20
Brasch, R C (1988) Ultrafast computed tomography for infants and children. Radiol Clin North Am 26:277-86
Eriksson, U G; Schuhmann, G; Brasch, R C et al. (1988) Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. J Pharm Sci 77:97-103
Paajanen, H; Grodd, W; Revel, D et al. (1987) Gadolinium-DTPA enhanced MR imaging of intramuscular abscesses. Magn Reson Imaging 5:109-15
Marotti, M; Schmiedl, U; White, D et al. (1987) Metal chelates as urographic contrast agents for magnetic resonance imaging. A comparative study. Rofo 146:89-93
Eriksson, U G; Ogan, M D; Peng, C T et al. (1987) Metabolic fate in the dog of the nitroxide moiety in a compound with potential utility as a contrast agent in MRI. Magn Reson Med 5:73-7

Showing the most recent 10 out of 40 publications